• Tofacitinib Citrate and Endothelial Inflammation

  2026-10-12

  A 2025 in vitro comparison found that JAK inhibitors consistently reduced inflammatory IL-6 release in cytokine-stimulated human endothelial cells, but their effects on adhesion, coagulation, and cell survival differed. The findings clarify a mechanistic research context for Tofacitinib citrate while remaining limited in their ability to predict cardiovascular outcomes in patients.

• hUC-MSCs, β-NGF and Postoperative Cognition

  2026-10-12

  A 2026 mouse study reports that human umbilical cord mesenchymal stem cells improved surgery-associated cognitive impairment and links the effect to β-NGF, TrkA, STMN2/NMNAT2, SARM1 and NF-κB signaling. The findings are mechanistically suggestive but remain preclinical and do not establish clinical efficacy or safety.

• PA-Ψ-seq Maps Pseudouridine on HIV-1 RNA

  2026-10-10

  Martinez Campos et al. introduced and validated PA-Ψ-seq, an antibody-based approach for locating pseudouridine residues across cellular and HIV-1 transcripts. The study identified transcript-specific contributions from several host pseudouridine synthases but found that HIV-1-associated Ψ sites were not altered by loss of PUS1, PUS7, or TRUB1/PUS4, leaving the dominant source of mRNA pseudouridylation unresolved.

• SIRT1, Bone Aging, and Vascular–Osteogenic Repair

  2026-10-09

  Liu et al. identify SIRT1 as a regulator of both endothelial activity and osteogenic differentiation in aged bone models, linking these effects to β-catenin deacetylation and nuclear Wnt signaling. The findings support a vascular–osteogenic framework for skeletal regeneration, while remaining preclinical and not evidence of clinical efficacy.

• Astragaloside IV, TUBB4B, and Pituitary Tumor Growth

  2026-10-09

  Li et al. identify a mechanistic link between astragaloside IV and the TUBB4B–STMN1–ERK signaling axis in pituitary tumor models. The study combines proliferation, apoptosis, molecular, pathway-inhibition, and xenograft evidence, while its translational relevance remains limited by the small human sample set and reliance on rat-derived cell models.

• Cy5-UTP in RNA Imaging: Evidence and Limits

  2026-10-08

  Cy5-UTP is a fluorescent uridine nucleotide analog used conceptually to visualize RNA in labeling, FISH, array, and delivery studies. This overview separates supplier claims from published evidence and explains why fluorescence tracking does not, by itself, establish RNA integrity, delivery, or biological activity.

• Dabigatran Etexilate: Oral Thrombin Inhibition

  2026-10-08

  The 2011 clinical review presents dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States, emphasizing its prodrug design, predictable anticoagulant effects, and clinical evaluation across venous thromboembolism and nonvalvular atrial fibrillation. Its significance lies in addressing practical limitations of vitamin K antagonists and parenteral anticoagulants, while the review also stresses renal-function considerations, hemorrhage risk, and the boundaries of the available evidence.

• Novobiocin, DNA Replication, and E. faecalis Protoplasts

  2026-10-07

  A 2020 study in Microbial Cell used Enterococcus faecalis protoplasts to examine whether DNA replication is linked to plasma membrane synthesis and vacuole formation during cell enlargement. The findings support a model in which replication inhibition restricts protoplast growth and prevents vacuole development, while also showing that the timing and duration of novobiocin exposure influence recovery.

• CCT007093: Rethinking PPM1D–p38 Biology

  2026-10-07

  A source-grounded perspective on CCT007093 as a PPM1D inhibitor, linking phosphatase control of P38 MAPK signaling with breast cancer cell cytotoxicity, renal tubular pyroptosis, and translational assay strategy.

• GPR107 Deficiency and Diabetic Nephropathy

  2026-10-06

  Xu et al. identify GPR107 as a regulator of AT1 receptor internalization in podocytes, linking defective endocytosis to collagen IV accumulation and diabetic nephropathy progression. The study’s cross-model evidence suggests a mechanistic connection between receptor trafficking, the angiotensin II signaling pathway, and glomerular basement membrane remodeling, while leaving clinical translation unresolved.

• Topotecan HCl and the DNA Damage Translation Gap

  2026-10-06

  Topotecan HCl offers a mechanistically defined way to interrogate replication-associated DNA damage, while new neuroinflammation research highlights how damage burden and repair capacity shape cell-type vulnerability. This thought-leadership perspective connects those findings without overextending oncology evidence into neurological claims.

• LncDACH1 and Smooth Muscle Switching in AVF

  2026-10-05

  A 2024 Nature Communications study identifies LncDACH1 as a regulator of smooth muscle cell phenotypic switching and neointimal hyperplasia in male arteriovenous fistula models. Its bidirectional genetic and viral perturbation strategy links LncDACH1 to an HSP90–SRPK1–AKT signaling axis and places KLF9 upstream of LncDACH1 transcription.

• Pam3CSK4 in Neuro-Immune Inflammation Research

  2026-10-04

  This overview distinguishes supplier-described properties of Pam3CSK4 from findings in a recent TRPV1 neuro-immune study. It explains how a TLR1/2 agonist could serve as a conceptual probe of immune–neural interactions while emphasizing that the supplied evidence does not directly connect Pam3CSK4 with the somato-autonomic reflex reported by Song et al. (2025).

• AM 281, GLT-1, and CB1 Signaling After TBI

  2026-10-03

  A 2025 Biomolecules study links traumatic brain injury to transient GLT-1 loss, CB1-CREB pathway disruption, neuronal apoptosis, and cognitive dysfunction in mice. Its findings position AM 281 as a pharmacological probe for testing how 2-AG and CB1 signaling influence astrocytic glutamate regulation, while remaining preclinical and model-specific.

• CCR7–Notch1 Crosstalk in Mammary Cancer Stemness

  2026-10-02

  Boyle et al. identified functional crosstalk between CCR7 and Notch1 in primary MMTV-PyMT mammary tumor cells, linking chemokine-receptor signaling to cancer stem-like behavior. Their findings suggest that evaluating both axes, rather than either pathway alone, may clarify mechanisms of stemness, recurrence, and therapeutic resistance.

8519 records 1/568 page Next 12345 下5页 Last page